YL217 for advanced solid tumors (first-in-human)
Part of Cancer clinical trials.
This study tests a new drug, YL217, for people with advanced solid tumors. It is a first-in-human trial, meaning this drug has not been tested in people before, and aims to see if it is safe and how well it works.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have a solid tumor that is advanced (has spread or cannot be removed by surgery).
- You have a tumor that can be seen on a scan (outside the brain).
- You have a stored tissue sample from a previous biopsy.
- You have not been treated with a drug that targets CDH17 or a similar type of ADC before.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called YL242 in people with advanced solid tumors that have not responded to prior treatment or have not been treated yet. It looks at safety, how well the drug works, and includes different groups based on cancer type and prior therapy.
This trial tests YL201 in people with advanced (late-stage) solid cancers when usual treatments don’t work or can’t be tolerated. The study looks at how the treatment is given, how safe it is, and how well it can shrink tumors.
This trial tests a combination of two new treatments (QLP2117 and QL2107) for people with advanced solid tumors that have not responded to standard therapy. The goal is to see if the combination can shrink tumors or slow cancer growth.
This trial tests a new drug, YL211, in people with advanced solid tumors that have not responded to standard treatments. It aims to see if the drug is safe and effective for cancers like lung, colorectal, stomach, pancreatic, liver, bile duct, and head and neck cancers.
This trial tests a new drug combination (YL201 and Ivonescimab) for people with advanced solid tumors that have stopped responding to other treatments. The goal is to see if this combination can shrink tumors or slow their growth.
This trial tests a new drug, CM518D1, for people with advanced solid tumors that have not responded to other treatments. It aims to see if the drug is safe and effective, and may offer a new option for those who have few choices left.
Hear when a new Advanced Solid Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.